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Abstract
IGF1R is emerging as an important gene in the pathogenesis of many solid and haematolo-
gical cancers and its over-expression has been reported as frequently associated with ag-
gressive disease and chemotherapy resistance. In this study we performed an investigation
of the role of IGF1R expression in a large and representative prospective series of 217
chronic lymphocytic leukaemia (CLL) patients enrolled in the multicentre O-CLL1 protocol
(clinicaltrial.gov #NCT00917540). High IGF1R gene expression was significantly associat-
ed with IGHV unmutated (IGHV-UM) status (p<0.0001), high CD38 expression (p<0.0001),
trisomy 12 (p<0.0001), and del(11)(q23) (p=0.014). Interestingly, higher IGF1R expression
(p=0.002) characterized patients with NOTCH1mutation (c.7541_7542delCT), identified in
15.5% of cases of our series by next generation sequencing and ARMS-PCR. Furthermore,
IGF1R expression has been proven as an independent prognostic factor associated with
time to first treatment in our CLL prospective cohort. These data suggest that IGF1Rmay
play an important role in CLL biology, in particular in aggressive CLL clones characterized
by IGHV-UM, trisomy 12 and NOTCH1mutation.
Introduction
Chronic lymphocytic leukaemia (CLL) is a common lymphoproliferative disorder character-
ized by heterogeneous clinical course. During recent years a number of prognostic markers
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have been proposed in order to distinguish between aggressive and indolent disease [1–3]. The
mutational status of the immunoglobulin heavy chain variable region (IGHV) represents one
of the most important prognostic markers in CLL and defines two disease subgroups: the first,
characterized by the absence of IGHV somatic mutation (IGHV-UM) in CLL cells, is associated
with the worst clinical course and outcome; the second presents IGHV somatic mutations
(IGHV-M) and has a more favorable prognosis and outcome [4,5]. However, a significant frac-
tion of IGHV-M patients also progresses and requires treatment, a finding that prompts the
identification of novel putative clinical and biological markers able to stratify progression risk
among these patients.
Insulin Growth Factor 1 receptor (IGF1R) is emerging as an important gene involved in
many solid and haematological cancers. Higher expression of the gene has been associated
with more aggressive disease and with pharmacological resistance [6]. Specifically the IGF1R-
IGF1/2 interaction is involved in the constitutive activation of many important intracellular
cell signalling pathways such as RAS/RAF/MEK/ERK kinases that stimulate cellular prolifera-
tion, or the phosphoinositide-3 kinase (PI3K)-Akt/mammalian target of rapamycin (mTOR)
pathway that predominantly mediates cell survival. Recently IGF1R was reported to be corre-
lated with the NOTCH1 signalling pathway in T-lymphoblastic leukemia where NOTCH1 acti-
vating mutations occur in more than half of patients [7]. In addition, the IGF1R was recently
tested as novel therapeutic target in solid malignancies and in multiple myeloma where IGF1R
inhibitors appear to overcome bortezomib resistance in the malignant plasma cell [8,9].
Although it has been described that IGF1R is heterogeneously expressed in CLL [10], its role
in the disease remains to be fully elucidated. Recently it was shown that IGF1R was generally
over-expressed in CLL compared to healthy B-cells, and was implicated in the activation of the
PI3K/Akt and MAPK pathways; notably, distinct CLL groups [i.e del(11)(q13), del(17)(p13)
and trisomy 12 patients] were found to be associated with a significant higher IGF1R expres-
sion compared to other patients [11].
Here we investigate the relevance of IGF1RmRNA expression in a large and representative
prospective series of Binet stage A CLL patients. In particular, we addressed its possible correla-
tions with biological, molecular and clinical outcome.
Materials and Methods
Patients
Newly diagnosed Binet stage A CLL patients from several Italian Institutions were prospective-
ly enrolled into the O-CLL1 protocol (clinicaltrial.gov #NCT00917540). Written informed con-
sent was obtained from all patients in accordance with the declaration of Helsinki and the
study was approved by the local Ethics Review Committee (Comitato Etico Provinciale, Mo-
dena, Italy). Diagnosis was confirmed by the biological review committee according to flow cy-
tometry analysis centralized at the National Cancer Institute (IST) as previously described [12].
Treatment was decided uniformly in all participating centres based on documented progressive
and symptomatic disease according to NCI-Working Group guidelines [2]. To date, 463 Binet
A CLL patients have been selected according to the inclusion criteria of the protocol. Two hun-
dred and seventeen CLL patients for whom RNA material was available were analysed by
means of GeneChip Gene 1.0 ST Array (Affymetrix) as previously described [12] and IGF1R
gene expression data have been inferred for each case. Gene expression data has been deposited
in the National Centre for Biotechnology Information’s Gene Expression Omnibus database
http://www.ncbi.nlm.mih.gov/geo and are accessible through series accession number
GSE51529. Biological and molecular analyses were performed in peripheral CD19+ B-cell
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samples collected from all patients within 12 months after diagnosis as previously described
[13,14].
CD38 expression was investigated as previously described and a 20% cut-off was chosen to
discriminate positive from negative patients [15]. Fluorescence in situ hybridization (FISH)
analyses of the most common cytogenetic deletions, IGHVmutational status and stereotyped
HCDR3 analysis were performed as previously described [16,17]. NOTCH1 c.7541_7542delCT
mutation was tested in 199 cases by next generation sequencing using the Roche 454 technolo-
gy and subsequently validated by Amplification Refractory Mutation System (ARMS)-PCR as
previously described [18].
According to the 1996 NCI guidelines [19], 162 (74.7%), 40 (18.4%) and 15 (6.9%) patients
were classified as Rai 0, Rai I and Rai II, respectively. However, based on the more recent Inter-
national Workshop on Chronic Lymphocytic Leukaemia (IWCLL) diagnostic criteria [2], 45
(20.7%) Rai stage 0 patients having less than 5.0x109/L circulating monoclonal B lymphocytes
were reclassified as clinical monoclonal B-lymphocytosis (cMBL). Patients’ clinical and biologi-
cal profiles are summarized in Table 1.
Real-Time Quantitative Polymerase Chain Reaction
IGF1R gene expression levels were analysed in purified CLL CD19+ cells by means of quantita-
tive real-time polymerase chain reaction (Q-RT-PCR) assay. Total RNA was converted to
cDNA using M-MLV reverse transcriptase (Invitrogen). Inventoried TaqMan Gene Expression
Assay (Hs00609566_m1) and the TaqMan Fast Universal Master Mix were used according to
manufacturer’s instructions (Applied Biosystems, Foster City, CA). 18S TaqMan Gene Expres-
sion Control (Hs99999901_s1) (Applied Biosystems) was used as the internal control. The
measurement of transcript expression was performed using the Applied Biosystems StepONE
Real-Time PCR System. All the samples were run in duplicate. Data were expressed as 2-ΔCt
(Applied User Bulletin No. 2).
Statistical Analysis
All contingency analyses were performed by Fisher’s exact test. Quantitative variables were
compared using the Mann-Whitney test. Time to First Treatment (TTFT) was defined as time
from diagnosis to first line treatment. Cox proportional hazards model was used in the global
test function of R software (under 100,000 permutation) to test the positive or negative
Table 1. Clinical and biological features of patients enrolled in the O-CLL1 protocol and investigated
by gene expression proﬁling.
All pts (217) MBL (45) CLL (172)
Median Monoclonal Lymphocytes 7789 × 106/L 3568 × 106/L 9152 × 106/L
CD38>20% 49/217 (26%) 12/45 (28%) 50/172 (29%)
IGHV-UM 84/216 (39%) 16/45 (35%) 68/172 (39.5%)
Normal Cytogenetic 79 (36.4%) 14/45 (31%) 65/172 (37%)
del(13)(q14)* 88 (40.6%) 17/45 (37%) 70/172 (41%)
Trisomy 12 28 (12.9%) 13/45 (29%) 15/172 (9%)
del(11)(q23) 16 (7.4%) 1/45 (2.2%) 16/172 (9.2%)
del(17)(p13) 6 (2.7%) 0/45 (0%) 6/172 (
NOTCH1 mutation 31/199 (15.5%) 8/38 (19%) 23/161
*As sole genomic aberrations
doi:10.1371/journal.pone.0118801.t001
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association between the IGF1R expression levels (as covariate, assumed as continuous variable)
and clinical outcome (as response variable, in terms of TTFT). Kaplan-Meier method was used
for TTFT curve estimation. Cox proportional hazard model was used for multivariate analysis.
P<0.05 was considered significant for all statistical calculations. All the analyses were per-
formed using appropriate functions in R software (www.r-project.org).
Results
We assessed the expression levels of the IGF1R gene in 217 cases included in a prospective co-
hort of Binet-A CLL patients. IGF1R expression showed a heterogeneous distribution, but no
difference was found between cMBL and other CLLs or Rai 0 patients (data not shown). The
levels of IGF1R transcripts were also validated by means of Q-RT-PCR in all samples for which
RNA was available (61 cases), and showed very good concordance with microarray data (Pear-
son correlation, r = 0.82) (S1 Fig.).
Interestingly among 217 tested patients, IGHV-UM cases were characterized by significantly
higher IGF1R expression compared to IGHV-M cases (p<0.0001) (Fig. 1A). This difference
was confirmed also if cMBL and CLL patients were considered separately (p = 0.004 and
p<0.0001, respectively). Stereotyped HCDR3 was identified in 70 cases (32%) (S1 Table),
mainly characterized by IGHV-UM configuration (p<0.0001). Patients with stereotyped
HCDR3 sequences showed greater IGF1R expression compared to non-stereotyped HCDR3
(p = 0.001); however, this could in all likelihood be related to the higher frequency of IGHV-
UM among stereotyped HCDR patients [45/70; 64%]. Among most frequent stereotyped sub-
set we observed a significant IGF1R overexpression among subset #1, #7, #8 and #10. These last
two stereotyped subsets were known to be strictly associated with IGHV-UM, IGHV4–39 utili-
zation and trisomy 12. Of note, subset #4 patients (known to exhibit an indolent clinical course,
unique IGHV-M and IGHV4–34 utilization and distinct biological profile [17,20]) were charac-
terized by lower IGF1R expression in all but one (1/10). This patient was the only one who pro-
gressed and required treatment among subset #4 subtype. Remarkably, IGF1R expression
differed significantly between subset #4 patients and IGHV-M patients (p<0.0001 and p = 0.03
respectively) (S2 Fig.).
Patients with CD38 positive expression were generally characterized by higher IGF1R ex-
pression in almost all cases (p<0.0001) (Fig. 1B). This significant association was confirmed
also if 30% was considered as CD38 positivity cut-off (data not shown). Higher IGF1R expres-
sion was also associated with unfavorable cytogenetic deletion [i.e. del(11)(q23) and del(17)
(p13)], particularly with del(11)(q23) (p = 0.014) (Fig. 1C-D). The association between unfa-
vorable cytogenetic deletions and IGF1R expression was not tested among cMBL due to the
lower prevalence of those aberrations in that subgroup of patients. However, cases with del(13)
(q14) as unique lesion, were characterized by the lowest IGF1R gene levels considering either
all patients (Fig. 1C) and cMBL or CLL separately (p = 0.0004 and p = 0.001, respectively). On
the contrary, among the most common cytogenetic aberrations, trisomy 12 showed stronger
IGF1R expression compared with the other patients (p<0.0001) (Fig. 2A). IGF1R was highly
expressed in almost all patients with trisomy 12 and this association was independent both
from cMBL/CLL classification and from IGHVmutational status. In fact considering only
IGHV-M patients, the presence of trisomy 12 was associated with a significantly higher IGF1R
expression compared to the others (p = 0.001) (Fig. 2B).
NOTCH1 c.7541_7542delCT mutation was previously investigated by next generation se-
quencing Roche 454 technology in 199 (91.7%) patients included in the present study [18]. We
considered as mutated only those patients (31 cases; 15.5%) in whom the presence of the dinu-
cleotide deletion was confirmed by ARMS-PCR [18]. In our present series, NOTCH1mutation
Insulin Growth Factor 1 Receptor in Chronic Lymphocytic Leukaemia
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was confirmed to be strongly associated with trisomy 12, IGHV4–39 gene usage and with
shorter TTFT in univariate analysis, whereas no difference in NOTCH1mutation prevalence
was observed comparing cMBL, with CLL or Rai 0 patients (data not shown). Interestingly, pa-
tients with NOTCH1mutation showed a greater IGF1R expression compared with wild type
cases (p = 0.002). In addition, high IGF1R expression was not significantly different comparing
patients with low and high NOTCH1mutation burden (data not shown). IGF1R was signifi-
cantly higher in NOTCH1mutated patients, either with or without trisomy 12, and in
NOTCH1 wt patients with trisomy 12, than in NOTCH1 wt cases without trisomy12 patients
(p = 0.0035, p = 0.0031 and p = 0.0002 respectively); no differences in IGF1R expression levels
were observed comparing any of the NOTCH1 wt without trisomy 12 counterpart groups
(Fig. 3). The correlation between NOTCH1 and IGF1R was also confirmed considering CLL
Fig 1. Boxplot of IGF1R expression (217 pts) in: A) IGHV-M vs IGHV-UM; B) CD38<20% vs CD38>20%; C) Most common cytogenetic aberrations
evaluated by FISH; D) unfavorable cytogenetic deletions (del11q23 and del17p13) vs other patients (favorable/intermediate FISH).
doi:10.1371/journal.pone.0118801.g001
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patients only (p = 0.001), conversely, among cMBL the association between IGF1R expression
and NOTCH1mutation did not reach statistical significance, although a partial trend was dem-
onstrated (data not shown).
Finally, in CLL patients (cMBL not included), increased IGF1R expression level was strongly
associated with aggressive clinical course and shorter TTFT (Fig. 4A).
Interestingly, IGF1R expression was also correlated with disease aggressiveness among
IGHV-M patients (Fig. 4B). Interestingly, none of the biological prognostic factors (i.e CD38,
ZAP-70, FISH) were able to predict clinical outcome in this group. Cox’s proportional hazard
model built including the most important biological variables revealed that IGF1R expression
represented an independent prognostic factor of TTFT in early stage CLL considering either all
CLL patients (Table 2) or only IGHV-M (Table 3). Among cMBL, IGF1R did not show a signif-
icant association with TTFT.
Discussion
IGF1R gene is known to regulate normal cell growth and contribute to transformation and pro-
liferation of malignant cells in many cell contexts [6]. This gene has been reported to play an
important role in haematological malignancies such as multiple myeloma, mantle cell lympho-
ma and T-cell acute lymphoblastic leukaemia (T-ALL) [7–9,21]. IGF1R was associated also
with favorable prognosis in breast cancer, non small cell lung cancer, soft tissue sarcoma and
classical Hodgkin’s lymphoma [22–27].
In CLL, it was recently reported that IGF1R is involved in the activation of phosphorylation
cascades such as Ras/Raf/MAPK and PI3K-Akt [28].These pathways are emerging as impor-
tant survival and proliferation signals in CLL and represent an attractive target of novel drugs
(i.e ibrutinib and idelasilib) [29–31]. In concordance with a previous study [11], we report the
strong association of IGF1R with unfavorable/intermediate cytogenetic aberrations, mainly tri-
somy 12. This association seemed independent of IGHV-UM, NOTCH1mutation or cMBL
status. Based on this data IGF1R could represent a potential novel candidate for specific tar-
geted therapy in this cluster of patients.
Fig 2. Boxplot of IGF1R expression in: A) Trisomy 12 vs no trisomy 12 patients; and B) Trisomy 12 vs no trisomy 12 considering only IGHV-M
patients.
doi:10.1371/journal.pone.0118801.g002
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Our data showed a strong association between IGF1R up-regulation and other unfavorable
biological features such as IGHV-UM and CD38 expression, differently from what reported by
Yaktapour et al [11]. In agreement with these biological associations, high IGF1R expression
was independently correlated with shorter TTFT among CLL patients and this association re-
tained its significance also considering only IGHV-M cases. Interestingly IGF1R did not
showed a unique association with the most common unfavorable prognostic factors, but its
high expression emerged both within trisomy 12 patients, known to have a intermediate
Fig 3. Boxplot of IGF1R expression in patients stratified according to trisomy 12 and NOTCH1mutation (mut: mutation; wt: wild-type; w/o:
without). IGF1Rwas significant higher among the NOTCH1mut/trisomy12, NOTCH1 mut/NOtrisomy12 and NOTCH1,wd/trisomy12 compared to other
patients (p = 0.0035, p = 0.0031 and p = 0.0002 respectively).
doi:10.1371/journal.pone.0118801.g003
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clinical course, and IGHV-M cases or other apparently favorable subgroups (i.e del13q14 as
single lesion) [3–5]. In fact, IGHV-M patients are generally characterized by indolent clinical
course, even if a significant fraction of these patients progressed and required treatment. To
date, no prognostic factor has proven to predict effectively clinical aggressiveness in these pa-
tients, and this observation was confirmed in our data set where no standard biological and
clinical features were able to predict clinical outcome in terms of TTFT among early stage
IGHV-M CLL patients (data not shown). In this context, IGF1Rmight represent a potentially
useful prognostic marker of TTFT among patients with theoretically indolent biological
(IGHV-M) and favorable clinical profile at diagnosis (Binet stage A). This suggestion is rein-
forced by the evidence that IGF1R retained its significant correlation in multivariate analysis.
Among cMBL, IGF1R expression could be an important indicator of disease aggressiveness al-
beit this needs to be validated in larger cohort with longer follow up.
IGF1R gene and protein levels and activity were recently reported to be strongly associated
with the NOTCH1 pathway in patients affected by T-ALL, in which it is frequently involved
and activated by mutations or molecular aberrations [7]. Activating NOTCH1mutations have
recently been reported by many groups as one of the most frequent aberrations in refractory
and transformed CLL [32–35]; NOTCH1 c.7541_7542delCT allelic variant represents the most
frequent aberration, accounting for more than 80% of all mutations [18,32–35]. According to
Fig 4. Kaplan-Meier estimated curves of time to first treatment according to IGF1R expression considering all CLL patients (A) and only IGHV-M
patients (B).
doi:10.1371/journal.pone.0118801.g004
Table 2. Cox multivariate analysis results considering only CLL patients.
Covariate p HR 95% CI of HR
CD38>20% 0.1037 1.6591 0.9045 to 3.0434
del(11)(q23) and del(17)(p13) 0.0783 1.8636 0.9353 to 3.7132
IGF1R expression 0.0258 1.0033 1.0004 to 1.0062
IGHV mutational status 0.0128 2.3390 1.2019 to 4.5519
HR: hazard ratio. CI: conﬁdence interval.
doi:10.1371/journal.pone.0118801.t002
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NOTCH1mutation data in our cohort, we observed that patients harboring NOTCH1
c.7541_7542delCT mutation were characterized by a significant IGF1R up-regulation. Thus, it
may suggest the existence of potentially altered signalling pathway, such as IGF1R, in CLL pa-
tients harboring NOTCH1mutation. Based on these data, IGF1R activity may provide an im-
portant growth and survival advantage to CLL cells, similar to what has recently been reported
in T-ALL [7].
Trisomy 12 was historically described as intermediate cytogenetic aberration characterized
by heterogeneous clinical course [3]. This was confirmed also in our prospective series where a
fraction of trisomy 12 patients showed an indolent clinical course, whereas the others had a
more aggressive evolution and short TTFT. This latter group was generally characterized by
IGHV-UM and/or high CD38, NOTCH1mutation, high IGF1R. In fact, patients with trisomy
12 showing low IGF1R expression, and IGHV-M and NOTCH1 wt status were generally char-
acterized by indolent clinical course. These data strengthen the potential role of IGF1R to dis-
criminate aggressive entities among “apparently intermediate” and/or “favorable CLL”.
Recent improvements in gene sequencing have demonstrated the importance of subclones
in cancer development. As reported in our previous study, NOTCH1mutation was defined as
subclonal in all patients with positive ARMS-PCR and negative by Sanger sequencing [18]. All
these patients were characterized by a mutation allele burden between 0.7 and 7%. Comparing
subclonal vs. clonal mutated NOTCH1 patients, no significant clinical or biological difference
was observed [18], and this was true also for IGF1R expression (data not shown). The potential
prognostic and biological role of subclonal gene mutations in CLL is a matter of debate
[18,36,37]; available data suggest that clonal and subclonal mutations share common clinical
and biological features, thus suggesting a potential perturbation of the same
signalling pathways.
Overall, our study shows the importance of IGF1R expression in CLL and its strong associa-
tion with specific adverse clinical and biological features, confirming the interest for the study
of this gene as a potential prognostic factor and its possible role as a therapeutic target in a spe-
cific group of CLL patients carrying trisomy 12 and NOTCH1mutations.
Supporting Information
S1 Fig. Q-RT-PCR validation of the microarray expression data. The correlation coefficients
of expression levels were assessed for all transcripts and are shown in the chart. Both the micro-
array and Q-RT-PCR data have been scaled in the range 0–1.
(TIF)
S2 Fig. Boxplots of IGF1R expression levels in subset #4, IGHV-UM and IGHV-M patients.
(TIF)
Table 3. Cox multivariate analysis results considering only IGHV-M CLL patients.
Covariate p HR 95% CI of HR
CD38>20% 0.070 1.3253 0,3075 to 5,7119
del(11)(q23) and del(17)(p13) 0.1446 4.5572 0,6002 to 34,5990
IGF1R expression 0.0094 1.0043 1,0011 to 1,0075
HR: hazard ratio. CI: conﬁdence interval.
doi:10.1371/journal.pone.0118801.t003
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